From the Guidelines
Tirzepatide is not currently approved or recommended for smoking cessation. Tirzepatide (brand name Mounjaro or Zepbound) is a GLP-1/GIP dual receptor agonist approved for type 2 diabetes management and weight loss, but it has not been studied extensively for smoking cessation. While some GLP-1 receptor agonists like semaglutide have shown preliminary evidence in reducing alcohol cravings and potentially other addictive behaviors in small studies, there is insufficient evidence specifically for tirzepatide's effect on smoking habits.
Key Points to Consider
- The most recent and highest quality studies, such as those cited in 1, do not support the use of tirzepatide for smoking cessation.
- Established first-line treatments for smoking cessation include:
- Nicotine replacement therapy (patches, gum, lozenges)
- Varenicline (Chantix)
- Bupropion (Zyban)
- These medications are often combined with behavioral counseling to address nicotine dependence through different mechanisms.
Recommendations
- If you're looking to quit smoking, consider using established first-line treatments under the guidance of a healthcare professional.
- Behavioral counseling and support can significantly enhance the effectiveness of pharmacotherapy interventions for smoking cessation, as noted in 1.
- Always consult with a healthcare provider before starting any new medication or treatment plan, especially when considering smoking cessation.
From the Research
Smoking Cessation Therapies
- The available evidence does not mention tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, as a therapy for smoking cessation 2, 3, 4, 5, 6.
- Current pharmacological strategies for smoking cessation include nicotine replacement therapy (NRT), varenicline, bupropion, and cytisine 2, 3, 4, 5, 6.
- Other therapies, such as nortriptyline, clonidine, and nicotine vaccines, have also been investigated for their potential in aiding smoking cessation 3, 4, 5, 6.
Emerging Therapies
- New pharmacological agents, including electronic cigarettes, selective serotonin reuptake inhibitors, and dopamine agonists, are being developed and investigated for their potential in smoking cessation 6.
- The development of new therapies aims to provide smokers with additional options to assist in achieving smoking cessation, as current therapies may not be effective for all individuals 6.
Treatment Selection
- The selection of a pharmacologic agent for smoking cessation should be based on the patient's comorbidities, preferences, and the agent's adverse event profile 2, 3, 4, 5, 6.
- A combination of behavioral support and pharmacologic therapy is recommended for smoking cessation, as outlined in the US Public Health Service Guideline 4.